| 05/04/2024 07:00:08 |
Response to Share Price Movement |
Download |
| 11/03/2024 07:00:04 |
Positive Results: Midkine mRNA and STAT-6 siRNA |
Download |
| 06/02/2024 07:00:03 |
Operations Update |
Download |
| 24/11/2023 07:00:09 |
Change of Auditor |
Download |
| 06/11/2023 07:00:13 |
Significant Mesodermal Killer Cell Milestone |
Download |
| 27/09/2023 07:00:06 |
Interim Results to 30 June 2023 |
Download |
| 22/09/2023 11:42:40 |
Investor Presentation via Investor Meet Company |
Download |
| 14/08/2023 07:00:04 |
Expansion of Patent Portfolio |
Download |
| 07/08/2023 07:00:05 |
Development of New Novel siRNA Therapeutics |
Download |
| 02/08/2023 07:00:07 |
Director/PDMR Shareholding |
Download |
| 12/07/2023 10:27:25 |
Director/PDMR Shareholding |
Download |
| 29/06/2023 10:05:01 |
Results of AGM |
Download |
| 29/06/2023 07:00:02 |
AGM Statement |
Download |
| 27/06/2023 07:00:05 |
Investor Presentation via Investor Meet Company |
Download |
| 26/06/2023 14:41:29 |
Director/PDMR Shareholding |
Download |
| 26/06/2023 10:36:26 |
Director/PDMR Shareholding |
Download |
| 26/06/2023 10:00:10 |
Director/PDMR Shareholding |
Download |
| 22/06/2023 07:00:08 |
RNA Medicine Shows In Vitro Anti-Cancer Efficacy |
Download |
| 19/06/2023 07:00:04 |
Antibody Program Results & Orphan Drug Indication |
Download |
| 13/06/2023 07:00:12 |
Anti-Cancer MDK mRNA - Positive in vitro Results |
Download |
| 07/06/2023 10:11:46 |
Restoration of Trading |
Download |
| 06/06/2023 07:00:08 |
Notice of Annual General Meeting |
Download |
| 05/06/2023 07:00:07 |
Annual Report & Financial Statements - 31 Dec 2022 |
Download |
| 02/05/2023 07:56:14 |
Suspension of Trading Pending 2022 Annual Report |
Download |
| 02/05/2023 07:30:02 |
Suspension - Roquefort Therapeutics plc |
Download |
| 13/03/2023 07:30:04 |
Confirmation of No Exposure to Silicon Valley Bank |
Download |
| 08/03/2023 07:00:06 |
Creation of New Novel Family of mRNA Therapeutics |
Download |
| 06/03/2023 07:00:02 |
Formation of Scientific Advisory Board |
Download |
| 01/03/2023 07:00:12 |
Company Presentation |
Download |
| 21/02/2023 07:00:08 |
Investor Presentation |
Download |
| 20/02/2023 07:00:03 |
Randox Licence and Royalty Agreement |
Download |
| 24/01/2023 07:00:03 |
MDK Oncology Antibodies Demonstrate In-Vivo Safety |
Download |
| 18/01/2023 08:36:18 |
Holding(s) in Company |
Download |
| 16/01/2023 07:00:06 |
Appointment of Auditor |
Download |
| 09/01/2023 07:00:01 |
Operations Update |
Download |
| 05/12/2022 08:07:52 |
Presentation of Midkine Oligonucleotide Program |
Download |
| 01/12/2022 14:00:06 |
Resignation of Auditor |
Download |
| 25/10/2022 07:00:06 |
Midkine Antibody Program - Festival of Biologics |
Download |
| 11/10/2022 07:00:17 |
ROQ Presents Study Results at the ESGCT Conference |
Download |
| 28/09/2022 07:00:12 |
Director/PDMR Shareholding |
Download |
| 26/09/2022 14:30:08 |
Director/PDMR Shareholding |
Download |
| 23/09/2022 07:00:06 |
Interim Results to 30 June 2022 |
Download |
| 16/09/2022 08:00:04 |
Investor Presentation |
Download |
| 16/09/2022 07:01:01 |
Board and Management Appointments |
Download |
| 16/09/2022 07:00:04 |
Acquisition Completion, Admission & Voting Rights |
Download |
| 15/09/2022 12:26:17 |
Notice of Admission |
Download |
| 13/09/2022 11:08:19 |
Publication of Prospectus |
Download |
| 11/08/2022 07:00:12 |
Pre-clinical Program & Transaction Update |
Download |
| 20/07/2022 07:00:09 |
Appointment of Joint Broker |
Download |
| 15/07/2022 07:00:05 |
Commencement of Trading on US OTCQB Venture Market |
Download |